From a clinical point of view, the contribution of a serum level of insulin and HOMA-IR is the same, as we demonstrated that insulin resistance is a key factor in the development of NASH and thus can be used as a therapeutic target. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.